Pluristem cleared to start Phase III PLX cell study for muscle regeneration in Germany
05:27 EDT 8 Aug 2012 | thePharmaLetter
In a second piece of good news this week, Israeli biotech company Pluristem Therapeutics (TASE: PLTR) revealed that it has received approval from the Paul-Ehrlich-Institute (PEI), the medical regulatory body in Germany, to commence a Phase III random..
Original Article: Pluristem cleared to start Phase III PLX cell study for muscle regeneration in Germany
More From BioPortfolio on "Pluristem cleared to start Phase III PLX cell study for muscle regeneration in Germany"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
